Overview A Study of SHR-A1811 in Subjects With Gynaecologic Oncology Status: Not yet recruiting Trial end date: 2026-06-15 Target enrollment: Participant gender: Summary This is an open-label, two-part study to evaluate the safety and efficacy of SHR-A1811 for injection in subjects with a gynaecological malignancies. Phase: Phase 2 Details Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.